Abstract: The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66? (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.
Type:
Grant
Filed:
November 24, 2017
Date of Patent:
April 7, 2020
Assignees:
Industry-University Cooperation Foundation Hanyang University, University of South Florida
Inventors:
Chul Geun Kim, Min Young Kim, Young Su Lim, Dae Hyun Ha, Young Yiul Lee, Buom Yong Ryu, Vladimir Uversky, Insung Na, Yu Chen, Arjan van der Vaart
Abstract: Compositions and methods for inhibiting, treating, and/or preventing fatty acid metabolism disorders, particularly fatty acid oxidation disorders, in a subject are provided.
Type:
Grant
Filed:
November 7, 2016
Date of Patent:
March 17, 2020
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Inventors:
Harry Ischiropoulos, Paschalis-Thomas Doulias
Abstract: Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized: Also provided are methods of using the solid forms.
Abstract: Disclosed are compounds of the formula (I) and (II): which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.
Type:
Grant
Filed:
April 10, 2018
Date of Patent:
March 3, 2020
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Saint Louis University
Inventors:
Kenneth A. Jacobson, Dilip K. Tosh, Daniela Salvemini
Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein (II), A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
Type:
Grant
Filed:
October 16, 2015
Date of Patent:
March 3, 2020
Assignee:
Sage Therapeutics, Inc.
Inventors:
Gabriel Martinez Botella, Francesco G. Salituro, Albert J. Robichaud, Boyd L. Harrison
Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
Abstract: The present disclosure provides compounds, compositions, and dietary supplements useful for the treatment of a body weight condition or a thyroid disorder. The compounds induce increased T3 levels while preventing thyroidal atrophy. Also provided are compounds, compositions, and dietary supplements useful for the treatment of a disease or condition that is estrogen sensitive, estrogen receptor dependent or estrogen receptor mediated such as breast cancer.
Abstract: Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and related medical uses are also described.
Type:
Grant
Filed:
May 14, 2013
Date of Patent:
October 29, 2019
Assignee:
University of Prince Edward Island
Inventors:
Tarek Saleh, Bobby Khan, Nadya Merchant
Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody.
Abstract: This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities. The anti-bacterial and anti-fungal compositions may be used to treat toe nail fungus, MRSA infection, herpes virus infection, tinea pedis, burn wound infections, sun burns, diabetic infections, eczema, impetigo, dermatophytosis, psoriasis, itchy skin, atopic dermatitis, dandruff, and general topical infections.
Type:
Grant
Filed:
March 5, 2019
Date of Patent:
October 15, 2019
Assignee:
Axim Biotechnologies, Inc.
Inventors:
George E. Anastassov, Lekhram Changoer, Philippus Anne Van Damme
Abstract: Aromatic farnesyl compound and application of a pharmaceutical salt thereof as an inhibitor of ?-glucosidase, dipeptidyl peptidase-4, aldose reductase, protein tyrosine phosphatase-1B or HMG-CoA reductase, or use thereof in preparing medicine and functional healthcare products having a liver protective function and/or for treating and/or preventing type II diabetes, diabetic retinopathy, diabetic foot disease, and hyperlipidemia.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
October 15, 2019
Assignee:
Institute of Microbiology, Chinese Academy of Sciences
Inventors:
Hongwei Liu, Kai Wang, Li Bao, Junjie Han
Abstract: There are provided pharmaceutical compositions comprising a compound of Formula (I) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Abstract: The present disclosure provides compositions and methods useful for the treatment of a body weight condition or a thyroid disorder. The compositions induces increased T3 levels while preventing thyroidal atrophy. Also provided are compositions and methods for the treatment of a disease or condition that is estrogen sensitive, estrogen receptor dependent or estrogen receptor mediated such as breast cancer.
Abstract: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterized by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
September 17, 2019
Inventors:
Paul Donnelly, James Hilton, Peter Crouch
Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.
Type:
Grant
Filed:
March 8, 2016
Date of Patent:
September 10, 2019
Assignee:
The Children's Mercy Hospital
Inventors:
Susan Abdel-Rahman, Barry L. Preuett, Steven J. Leeder
Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
September 3, 2019
Assignee:
Actimed Therapeutics Limited
Inventors:
Andrew J.S. Coats, Stefan Anker, Jochen Springer
Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
September 3, 2019
Assignee:
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Abstract: The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.
Type:
Grant
Filed:
December 12, 2016
Date of Patent:
August 13, 2019
Assignee:
Berg LLC
Inventors:
Joaquin J. Jimenez, Niven Rajin Narain, Rangaprasad Sarangarajan, John Patrick McCook
Abstract: Provided are methods of treating skin with at least two alternating treatment modalities to improve the health and/or diminish signs of aging. Some methods according to the present invention may comprise topically applying at least two separate compositions, in a sequential, rotating, or alternating fashion to overcome adaptation, tolerance, or sensitization phenomena.
Type:
Grant
Filed:
March 4, 2016
Date of Patent:
June 25, 2019
Assignee:
Avon Products, Inc.
Inventors:
Simon Dutton, Daniel Thorn Leeson, Jeanine Schoen, Dana Von Bargen, Uma Santhanam, Jolanta Idkowiak-Baldys, Anthony David Gonzalez, Pradeep H. Yadav, Olga Maria Martinez-Avila, Lauren Policelli, Glen Thomas Anderson, Russell J. Wyborski